Erlotinib, erlotinib-sulindac versus placebo: a randomized, double-blind, placebo-controlled window trial in operable head and neck cancer

Neil D. Gross, Julie E. Bauman, William E. Gooding, William Denq, Sufi M. Thomas, Lin Wang, Simion Chiosea, Brian L. Hood, Melanie Flint, Mai Sun, Thomas P. Conrads, Robert L. Ferris, Jonas T. Johnson, Kim Seungwon, Athanassios Argiris, Lori Wirth, Marina N. Nikiforova, Siegfried Jill M., Grandis Jennifer R.

Research output: Contribution to journalArticle

Original languageEnglish
Pages (from-to)3289-3298
Number of pages10
JournalClinical Cancer Research
Volume20
Issue number12
DOIs
Publication statusPublished - 11 Apr 2014

Cite this

Gross, N. D., Bauman, J. E., Gooding, W. E., Denq, W., Thomas, S. M., Wang, L., Chiosea, S., Hood, B. L., Flint, M., Sun, M., Conrads, T. P., Ferris, R. L., Johnson, J. T., Seungwon, K., Argiris, A., Wirth, L., Nikiforova, M. N., Jill M., S., & Jennifer R., G. (2014). Erlotinib, erlotinib-sulindac versus placebo: a randomized, double-blind, placebo-controlled window trial in operable head and neck cancer. Clinical Cancer Research, 20(12), 3289-3298. https://doi.org/10.1158/1078-0432.CCR-13-3360